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PresenilinThe brains of the adult mouse and human possess neural stem cells (NSCs) that retain the capacity to
generate new neurons through the process of neurogenesis. They share the same anatomical locations of
stem cell niches in the brain, as well as the prominent feature of rostral migratory stream formed by
neuroblasts migrating from the lateral ventricles towards the olfactory bulb. Therefore the mouse possesses
some fundamental features that may qualify it as a relevant model for adult human neurogenesis. Adult born
young hippocampal neurons in the mouse display the unique property of enhanced plasticity, and can
integrate physically and functionally into existing neural circuits in the brain. Such crucial properties of
neurogenesis may at least partially underlie the improved learning and memory functions observed in the
mouse when hippocampal neurogenesis is augmented, leading to the suggestion that neurogenesis
induction may be a novel therapeutic approach for diseases with cognitive impairments such as Alzheimer's
disease (AD). Research towards this goal has beneﬁted signiﬁcantly from the use of AD mouse models to
facilitate the understanding in the impact of AD pathology on neurogenesis. The present article reviews the
growing body of controversial data on altered neurogenesis in mouse models of AD and attempts to assess
their relative relevance to humans.ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Regenerative medicine offers new hope for patients suffering
from impairments associated with degeneration, wounds and aging.
In theory, regenerative therapy is an attractive approach because
through the regeneration and/or correction of lost or altered cellular
functions, it may help to reverse functional decline to an extent that
raises the patient's physiological function above the threshold for
disease onset. Therefore regenerative medicine could at least
supplement current therapeutic strategies, which are predominantly
symptom relief approaches or strategies that aim at slowing down or
stopping the progression of the disease. Regenerative medicine can
come in different guises, including the transplant of organs and cells
such as the heart and bone marrow cells, which have been in clinical
practice for decades. Alternatively, the regenerative activities of
endogenous stem and progenitor cells residing in the body can be
induced by drugs, such as the recently approved Eltrombopag and
Romiplostim which stimulate the proliferation and differentiation of
megakaryocytes to give rise to platelets for the treatment of thrombo-
cytopenia in patients with chronic immune (idiopathic) thrombocy-
topenic purpura (ITP) [1]. Several diseases of the CNS involve the loss
of neural cells and may therefore beneﬁt from regenerative therapies.
These diseases include Alzheimer's disease (AD), Parkinson's disease,
stroke, Huntington's disease, multiple sclerosis, motor neuron disease,spinalmuscular atrophy, and spinal cord injuries. None ofwhich canbe
treated effectively by current therapies, therefore numerous novel
medicines are being developed and studies toward the development of
regenerative therapeutics have also been accelerating. The endoge-
nous generation of neurons from neural stem cells (NSCs) in the adult
brain is an exciting area that could impact some of these diseases. The
current article reviews the developments in neurogenesis research
with particular focus on the involvement of neurogenesis in AD as
gleaned from mouse models of the disease.
AD is a progressive neurodegenerative disease that could last for up
to 20 years, undergoing different disease stages with mild, moderate
to severe cognitive decline. The autosomal dominant familial form of
the disease (FAD) occurs in only about 5% of the patient population and
is the result of mutations in the genes for amyloid precursor protein
(APP), presenilin 1 (PS1) or PS2. PS is a member of the γ-secretase
complex that acts in conjunction with β-secretase in cleaving APP to
release beta amyloid (Aβ) peptides of varying lengths. Aβ peptides
with 40 (Aβ1–40) and 42 (Aβ1–42) amino acids are the predominant
species and Aβ1–42 the most toxic species [2]. So far, 25, 150 and 10
mutations have been identiﬁed in the genes for APP, PS1 and PS2
respectively (http://www.molgen.ua.ac.be/ADMutations). The more
frequent form of the disease is late-onset sporadic ADwhich describes
the non-familial form of the disease that occurs in the remaining
patient population. It is thought to be caused by a multitude of
environmental factors as varied as aging, stress, glucose intolerance,
cardiovascular factors, obesity and educational background [3], aswell
as a host of genetic risk factors with a polymorphism within the ApoE
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[4]. Despite such varied array of potential etiological factors, the
deﬁning diagnostic criteria for all AD patients include the accumulated
Aβ peptides and plaques, as well as hyperphosphorylated tau proteins
(P-tau) that form the major constituent of intracellular neuroﬁbrillary
tangles (NFTs), in conjunctionwith loss of neurons and synapses [5,6].
Therefore, these features have formed the basis of transgenic mouse
models for the study of AD despite their accepted “incompleteness”;
the pros and cons of these models have been discussed extensively
[7–9].
The “gold standard” drugs for AD patients are the cholinesterase
inhibitors such as Aricept [10,11], which serve to improve the symp-
toms temporarily in a portion of the patients. Many other drugs for
symptomatic relief aswell as diseasemodiﬁcation are being developed
[12], and regenerative strategy, through the induction of endogenous
NSCs and neural progenitor cells (NPCs), could potentially provide a
novel therapeutic approach.
2. Neurogenesis in the adult human brain
Effective homeostatic regulation maintains the healthy status of a
living organism through amultitude of dynamicmechanisms, and one
such mechanism is the regeneration of cells and tissues. Similar to
other homeostatic regulatory systems, endogenous regeneration is a
dynamic process that responds quantitatively and qualitatively to the
body's needs. This regenerative capacity is most explicitly demon-
strated in the planarian fresh water worm,which is able to completely
regenerate a whole organism when its body has been segmented at
any point [13]. This function has been preserved through evolution
though its prowess appears to diminish along the phylogenetic tree
towards the primates. The most evident examples of regeneration in
humans are the continuous generation of hair from follicular stem
cells [14], and the regeneration of skin following an injury [15].
Internal tissues such as the intestine can also regenerate [16], and the
brain is no exception.
The adult brain possesses NSCs which are able to give rise to new
neural cells through the process of neurogenesis, which comprises a
series of cellular events that include the proliferation of NSCs and their
differentiation into NPCs, which can migrate, proliferate and differ-
entiate into functional mature neurons, or into astrocytes through
astrogenesis, and oligodendrocytes through oligogenesis. The in-
volvement of these sequential but separate steps in the formation of
mature cells would stipulate that changes in merely one or more
steps in the process of neurogenesis would not necessarily alter the
formation of functional mature neurons (see Fig. 1). For example, an
increase in the proliferation rate would not result in increased
number of mature neurons if the progenitors and/or neuroblasts fail
to survive or differentiate. It is however important to recognise that
since NSCs and NPCs produce a range of trophic and anti-inﬂamma-Fig. 1. Mechanisms of neurogenesis. Neural stem cells support brain functions through the
progenitors andmature neurons. The process of neurogenesis can be subdivided into indepen
can be regulated by an independent factor.tory factors [17,18], the expansion of the NSC/NPC pools without
generating mature neurons could by itself exert functional beneﬁts,
as exempliﬁed by the therapeutic effects of BDNF released from
implanted NSCs in an AD mouse model [17].
Early suggestions of neurogenesis in postnatal and adult mamma-
lian brains were published around the turn of the 20th century [19].
However the lack of suitable techniques held the ﬁeld back until the
1960s when the incorporation of [3H]-thymidine into the DNA of
proliferating cells was developed to label and identify new born cells
which were revealed by autoradiography. Despite the inability of this
technique to deﬁnitively resolve the identity of the labelled cells, this
technique enabled Joseph Altman to conduct a series of seminal
studies in the 1960s to demonstrate that new neurons could be
generated in the olfactory bulb and the hippocampus of postnatal and
adult rats [20–22]. These were later conﬁrmed and extended by
Michael Kaplan in a series of [3H]-thymidine studies in rodents and in
non-human primates, which was published as recently as 1985
[see 1]. Although the concept of neurogenesis remained in the shadow
despite these groundbreaking ﬁndings, they had prepared the ground
for the ﬁnal spur when further techniques were developed. These
include the labelling of the nuclei of proliferating cells with the
thymidine analogue 5-bromo-2-deoxyuridine (BrdU), and the avail-
ability of antibodies for cellularmarkers for NSCs, NPCs, and immature
and mature neural cells [23], as well as the development of confocal
microscopy enabling the detailed analysis of new born cells to conﬁrm
the existence of neurogenesis in different species of animals, including
the song birds, mice and monkeys [24–26]. The climax of the consoli-
dation of this phenomenon was reached in 1998 when the laboratory
of Fred Gage reported the existence of neurogenesis in the adult
human brain [27]. This landmark report was supported by the dem-
onstration that NSCs could be isolated from the brain of the adult
mouse [28] as well as the adult human [29–31]. Altogether, a body of
evidence supports the notion that the adult human brain is endowed
with NSCs and active neurogenesis throughout life.
NSCs reside in two niches in the adult human brain, namely the
subgranular zone (SGZ) of the dentate gyrus (DG) in the hippocampus
and the subventricular zone (SVZ) lining the lateral ventricles [32,33].
Although NSCs isolated from these brain regions are able to differ-
entiate in vitro into neurons, astrocytes and oligodendrocytes, it was
necessary to prove their physiological relevance by providing in vivo
data on the ability for new born neurons during adulthood to
integrate into functional neural circuits, and to affect physiological
functions. To this end, morphological, lineage tracing and electro-
physiological studies in the DG of adult mice have revealed in detail
the development of new neurons, providing convincing evidence that
new neurons generated in the adult rodent brain can develop into
functional neurons that fully integrated into the existing neural cir-
cuitries. Furthermore, the fate of new neurons is strongly determined
by environmental factors such as enriched environment, which cancreation of new neurons and the release of soluble trophic factors by neural stem cells,
dent mechanisms (proliferation, differentiation, survival and migration), each of which
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These studies have been extensively reviewed recently [32].
A role for neurogenesis in brain functions was implicated by the
strategic location of NSCs in the DG of the hippocampus, a region
known to be involved in cognitive functions such as learning and
memory, as well as the interaction between environment and
neurogenesis. Consequently a large number of in vivo studies have
been conducted in mouse models of cognition to test this hypothesis.
While these studies are not unequivocal in supporting a direct cor-
relation between the rate of neurogenesis and cognition, nor are they
conclusive on the speciﬁc types of memory tasks that are sensitive to
neurogenesis, the majority do reveal a trend for a positive correlation
between enhanced cognitive function and the rate of neurogenesis
(Table 1). Further impetus is added by the demonstration that young
neurons exhibit heightened levels of morphological and electrophys-
iological plasticity during a brief period before reaching complete
maturity, and that the young neurons have a greater tendency to
become integrated into the neural networks of spatial memory tasks
in the mouse [reviewed in 32]. It is with such increased conﬁdence in
the relevance of neurogenesis in brain functions that an examination
of its involvement in AD diseases became relevant.
3. The study of neurogenesis in AD models
The functional impact of neurogenesis on learning and memory
suggests its involvement in AD because poor memory function can
predict AD up to 15 years before diagnosis [51], which continues to
decline during the course of the disease. There has therefore been an
increasing level of interest in understanding whether the process of
neurogenesis is altered in the disease and thus contributes to cogni-
tive impairment. For this purpose, the mouse models that were
developed to recapitulate at least some features of AD pathology have
provided important insights.Table 1
Correlation between cognitive function and hippocampal neurogenesis. The rate of
neurogenesis in mice were modiﬁed (↓=decrease, ↑=increase) by multiple factors
and their cognitive functions tested in different tasks. A positive correlation between
the changes in neurogenesis rate and cognitive function is indicated by✓, whereas the
lack of effect on neurogenesis is indicated by X.
Neurogenesis Factors Tasks Correlation Reference
↓ Irradiation W/maze⁎ X [34]
↓ Irradiation W/maze⁎ ✓ [35]
↓ Irradiation Barnes maze ✓ [36]
↓ Irradiation W/maze⁎ X [36]
↓ MBD1 −/− W/maze⁎ ✓ [37]
↓ NT-3 −/− W/maze⁎ ✓ [38]
↓ Immunodeﬁciency W/maze⁎ ✓ [39]
↓↑ Strain W/maze⁎ ✓ [40]
↓ Neurokinin-1-R−/− Trace/contextual
fear conditioning
X [41]
↓ Neurokinin-1-R−/− W/maze⁎ X [41]
↓ Irradiation and
NSC ablation
Contextual fear
conditioning
✓ [42]
↓ Irradiation and
NSC ablation
W/maze⁎ X [42]
↓ Irradiation and
NSC ablation
Radial maze Inverse
correlation
[43]
↓ Temozolomide W/maze ﬂexibility ✓ [44]
↓ Irradiation Radial arm maze
& touch screen
✓ [45]
↑ Environment
enrichment
W/maze⁎ ✓ [46]
↑ Environment
enrichment
W/maze⁎ ✓ [47]
↑ Exercise W/maze⁎ ✓ [48]
↑ Exercise W/maze⁎ ✓ [49]
↑ Exercise W/maze⁎ ✓ [50]
↑ Exercise Contextual fear
conditioning
X [50]
⁎W/maze=Morris water maze.4. Mutant APP models
The ﬁrst reports on alterations in the process of neurogenesis in an
AD mouse model were from the laboratory of Mattson using
transgenic mice expressing the APP gene harbouring the Swedish
familial AD double mutation [52,53]. Through the use of BrdU to label
proliferating cells and double labelling for E-NCAM to identify new
born neurons, Haughey et al. reported reductions in the proliferation
of NPCs in the SGZ of the DG as well as the SVZ. Moreover, the survival
of newborn neurons in the CA3 regionwas reduced. These suppressive
effects were observed only in 12-month-old mice when Aβ deposits
were present, but not in youngermicewithout Aβ deposits. These data
were accompanied by in vitro studies demonstrating the suppressive
and toxic effects of Aβ1–42 on human and mouse NPCs [52,53].
Together these two studies provided the ﬁrst indication that a key
toxic component in AD pathology exerts suppressive effects on some
neurogenesis mechanisms, thereby reducing the neurogenesis poten-
tial. Although these early data provided a sound case, supported by a
study showing that the survival of new born neurons was compro-
mised in another Swedish familial AD line [54], the formation of
mature neurons were not examined, therefore these early reports
were not adequate to sustain that mutant APP, via increased produc-
tion of Aβ, could lead to reductions in the formation of new mature
neurons.
The studies of Haughey et al. [52,53] demonstrate a correlation
between the development of Aβ deposits and suppression of NPC
proliferation, but some other reports indicate that the suppression of
proliferation initiated during pre-deposit stages when soluble oligo-
meric Aβ can already be detected in the brain [55]. This possibility is
intriguing due to themounting evidence against a correlation between
plaque number and AD severity, instead a robust correlation has been
observed between soluble Aβ levels and the extent of synaptic loss and
severity of cognitive impairment [56–59]. These clinical ﬁndings are
supported by a string of preclinical studies demonstrating that cogni-
tive functions appear to be impaired by soluble oligomeric Aβ rather
than Aβ deposits [60–64]. In the Tg2576 transgenic mouse line which
expresses the APP gene harbouring the Swedish familial AD double
mutation under the regulation of the PDGF promoter, soluble oligo-
meric Aβ1–42 assemblies can be detected at least 3 months before the
deposition of insoluble Aβ at the age of 9 months [61,62]. At this pre-
deposition stage, theNPC proliferation rate in DGwas already reduced,
as it was during the later stages when Aβ deposits became apparent
[65]. Similarly, in a separate linewith double Swedish and London APP
mutations under the regulatory control of the murine (m)Thy-1 gene,
reduced SGZ proliferation and neuroblasts were also observed as early
as 3 months of age,whenAβdepositswere observedonly in the frontal
cortex but not in the hippocampus [66]. Although the levels of soluble
Aβ1–42were not analysed in thesemice, it is inferred from the Tg2576
[67,68] and J20 [69] mutant APP mouse lines that diffusible extra-
cellular oligomeric Aβ assemblies are present in conjunction with
insoluble deposits, hence the SGZwould have been exposed to soluble
Aβ.
Since behavioural study and quantiﬁcation of new born mature
neurons in the above mice were not performed, the functional impact
of reduced proliferation in these mice remained unknown. However,
irrespective of whether the suppression of proliferation did result in
reduced number of new born neurons, suppression of NSC/NPC
proliferation may result in reduced pools of NSCs/NPCs, which alone
may contribute to cognitive deﬁcits because a recent study demon-
strates that transplantation of NSCs could improve cognition through
their production of BDNF [17]. Intriguingly, the underlyingmechanism
mediating the BDNF effect was dependent on enhanced hippocampal
synaptic density, indicating that expansion of hippocampal NSC popu-
lation via enhanced proliferation could improve cognitive functions.
The in vivo overproduction of Aβ in mutant APP transgenic mice
does not consistently suppress the process of neurogenesis in all the
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with a study by Jin et al. on post-mortem hippocampal samples from
patients in different stages of AD expressed increasing levels of
markers of immature neurons with increasing disease severity [70].
This study did not report on other components in the neurogenesis
process, namely proliferation or the formation of newmature neurons,
therefore it could not conclusively suggest that the formation of
mature neurons is increased in AD. Two other studies on post-mortem
AD brain report reduced numbers of SVZ NSCs and unchanged SGZ
proliferation [71,72]. Although the parameters examined in these
three human studies are different, they do provide conﬂicting data that
precludes any clear conclusion. Jin et al. followed up the human study
with an in vivo study on the PDGF–APPSWE,Ind (J20) mice which carry
both the Swedish and Indiana APP mutations, reporting increases in
proliferation in the SGZ during pre- and post-Aβ deposition stages,
concomitant with increases in the quantity of new born immature
neurons, though no statistical analysis was reported on the latter [73].
The increase in hippocampal proliferation andneuronal differentiation
in this same mouse line at the pre-deposition stage was also reported
in a separate study, although the increases reverted when the mice
became older [74]. Since the changes in neurogenic rates in both
studies were independent of Aβ deposits, when oligomers were
detected, this effect was attributed to oligomeric Aβ [74]. This hypoth-
esis is in part supported by several in vitro studies demonstrating the
induction of NPC proliferation and neuronal differentiation by soluble
oligomeric Aβ1–42 peptides [75–77]. Further confounding data is
provided by APP23 mice which express the APP gene harbouring the
Swedish familial AD double mutation under the Thy-1 promoter [78],
and by the Tg9291 mice carrying three different APP mutations [79],
both showing increased proliferation only in the aged animals with
high levels of Aβ deposits, but not in young animals without Aβ
deposits. Suchdependency of NPCproliferation on age andAβdeposits
is analysed more extensively in a pNes-Tg X pPDGF–APPSWE,Ind line
which expresses lacZ inNPCs, thus enabling the quantiﬁcation of NPCs,
in addition to the proliferation rate and neuronal differentiation
[80]. The DG, SVZ and prefrontal cortex of the mice were analysed at
the ages of 2 months (no plaques), 8 months (onset of plaques) and
12 months (high levels of plaque accumulated). The data indicate
multi-phased alterations in the parameters as the age of the mice
increased and as the Aβ deposition advanced, with a trend for
increased proliferation prior to the onset of Aβ deposition, which
subsequently decreased in concomitance with elevated Aβ deposits.
Furthermore, the presence of Aβ plaques appeared to induce neuronal
differentiation in the DG. This extensive dataset serves as a notice that
the dynamic process of neurogenesis comprises a sequence of events
that can react extensively to the changing environment. The brain
environment created by the overproduction of various Aβ peptides
which slowly polymerise into multiple forms is complex. The com-
plexity is illustrated by the highly variable effects of different Aβ
species on NPC proliferation and differentiation even in the well
controlled setting of in vitro experiments with Aβ1–40 and Aβ1–42
peptides. On neuronal differentiation, one study found that only the
oligomeric and small aggregated forms of Aβ1–42 had positive effects,
while freshly solubilised Aβ1–42 and all forms of A1–40 were ineffec-
tive [75]. A second study found that Aβ1–40 and Aβ1–42 induced
neuronal and astrocytic differentiation respectively [76], whereas a
third study found that both the freshly prepared monomeric and
oligomeric Aβ1–42 induced neuronal differentiation, with the ﬁbrillar
formhaving no effects [77]. On proliferation, the effects can range from
increase [76,77], no effect [75] or decrease [52,53], with no apparent
correlation with the Aβ peptide length or with the oligomeric and
aggregated states. A further signiﬁcant complication arises from bell-
shaped dose-dependent responses to the Aβ peptides [75,77]. These
variable biological activities of Aβ peptides would be expected to
synergise in the mouse brain, and the complexity is further ampliﬁed
by the effects of Aβ peptides on the cellular environment in the braine.g. inﬂammation with its associated cellular and cytokine factors that
are known to affect NPC proliferation and differentiation [see 32 for
review].
The reports on the in vivo mutant APP models present a trend for
suppressed neurogenesis in mice with single APP mutations, but the
effects of expressing more than one APP mutation in just a handful of
studies are more confusing and require further research to strengthen
the understanding. Nevertheless, all the above studies examined only
the steps of proliferation and differentiation without data on the
formation of new mature neurons. Since proliferation and differen-
tiation are but two steps in the process of neurogenesis, and large
percentages of new born neurons in the DG do not survive to maturity
[81], the changes in the rates of these two steps may have no bearings
on functional outcome if the number and functional status of mature
neurons are not affected. To date, only the study by Donovan et al. has
attempted to address these crucial endpoints of neurogenesis [82]. In
the PDAPP mice that carry the Indiana mutant APP, proliferation rate
in the SGZ was unaltered at 2 months of age, but became signiﬁcantly
reduced at the age of 1 year when plaques developed (Fig. 2 a).
However the number of proliferative cells did not correlate with
plaque load, suggesting that the decreased proliferation was inde-
pendent of insoluble Aβ or plaque accumulation. Importantly, the
reduction in proliferation was paralleled by a reduced total number of
neuroblasts (DCX+) in the SGZ. Surprisingly in the outer granule cell
layer (oGCL) which borders the SGZ, and into which new born cells
from SGZ migrate to, the quantities of 4-day-old neuroblasts (DCX/
BrdU+) had increased. This is unusual because new neuroblasts at
such a young age in control mice would not have migrated out of SGZ
into oGCL. This ﬁnding is therefore strongly suggestive of ectopic
neuronal differentiation (Fig. 2 c–e). When the new born neurons
were analysed 4 weeks after birth, their survival rate was lower than
in the control mice (Fig. 2 b). Furthermore the orientation, morpho-
logical and staining features of these cells in GCL were signiﬁcantly
different from those in the control mice (Fig. 2 c–d). Finally, impaired
neuronal development in these mice was conﬁrmed by the reduced
GCL volume and total cell numbers. It is noteworthy that reduced
DG volume prior to plaque formation in the Indiana mutant APP
mouse has also been detected by magnetic resonance imaging [83].
Therefore, this elegant study provides an interesting scheme in which
the reduced proliferation rate in SGZ is accompanied by increased
ectopic differentiation in oGCL towards the neuronal lineage,
producing apparently abnormal neurons thatmay have lower survival
rates, eventually resulting in reduced mature neurons and cell num-
bers in the GCL. This series of detailed analysis by Donovan et al.
provide a useful example of the degree of thoroughness that may be
required to help understand the functional impact of neurogenesis
alterations. Further studies will be needed to conﬁrm these ﬁndings,
and electrophysiological data will be needed to further examine the
biology of the new born neurons created in the AD mouse models.
5. Mutant PS models
FAD mutations in PS1 or PS2 cause gain of toxic function through
increases in the ratio of Aβ1–42/1–40 peptides, though they do not
lead to the formation of plaques and induce weak behavioural deﬁcits
[2,8,9,84], and in this way the mutant PS mice provide an extension to
the mutant APP mice for examining the effects of soluble Aβ on
neurogenesis. However, there is the caveat that PS has numerous
other physiological functions through the multiple cellular pathways
that it acts on [2], therefore it is recognised that the effects of PS
mutations could bemediated by numerous mechanisms in addition to
its effects on APP processing. Further complications could arise from
the N150 known PS mutations, which could differentially affect the
interactions with its partners and hence neurogenesis.
PS-1 null mice are not viable and exhibit severe developmental
defects that include a fundamental failure in neurogenesis [85],
Fig. 2. Reduced proliferation, survival and ectopic neuronal differentiation in the dentate gyrus of PDAPP mice. a. Reduced counts of proliferating (BrdU-IR) cells in the dentate gyrus
of 1-year-old PDAPP mice, in the subgranular zone (SGZ) and molecular layer (Mol) relative to wild type (WT) mice. The outer granular cell layer (oGCL) and Hilus (Hil) showed no
signiﬁcant differences in proliferation. Inset: no signiﬁcant differences were found between 2-month-old PDAPP and WT mice. b: Counts of 4-week-old BrdU-IR cells in the dentate
gyrus of 1-year-oldWT and PDAPPmice revealed fewer surviving in both SGZ and oGCL of PDAPPmice. c–e. PDAPPmice (d) havemore 4-day-old Dcx-IR neuroblasts (brown cells) in
the oGCL relative to WT mice (c). Quantiﬁcation of Dcx-IR cell in the SGZ and oGCL is depicted in (e).
(Reprinted from reference [82] with permission from John Wiley and Sons).
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strated in the adult with conditional PS knockout mice [86], an
approach that has been used in several studies. However the loss of
the holoprotein is not a known feature of AD, therefore these studies
are not reviewed in this article. Instead only the studies involving FAD
PS mutations will be included herein.
In the lines expressing P117L PS1 under the neuron-speciﬁc enolase
promoter, Wen et al. demonstrated that the mutant had reduced
capacity in maintaining the survival of NPC speciﬁcally in the SGZ but
not in the SVZ [87,88], and the reduction in NPC survival was paralleled
by reduced levels of differentiation into new mature neurons in the
mutant mice [88]. These mice did produce elevated levels of Aβ1–42
without affecting Aβ1–40. Therefore these studies provide further
evidence supporting the suppressive effects of soluble Aβ1–42 on
neurogenesis, though the possible involvement of other mechanisms
has also been considered [88]. One such mechanism formed the basis
for the study byChevallier et al.who set out to examine the effect of PS1
A246E mutation on the Wnt/β-catenin signalling pathway and SGZ
neurogenesis. This Thy-1 promoter regulated mutant did result in
increased SGZproliferation, but signiﬁcantly this failed to translate into
increased numbers of new born neurons [89].
In order to provide a model with the endogenous pattern of tissue
distribution and expression levels, the PS1 M146V knockin mice were
backcrossed onto a PS1-null background to produce a model that
expresses the human PS1 mutant in the absence of endogenous
mouse PS [90]. At 3 months of age, proliferation and formation of
new born neurons in SGZ was reduced, concomitant with impaired
hippocampal-dependent associative learning paradigm. Therefore,
through the use of the PS1 mutant knockin/PS1 null strategy, this
study provides the most physiologically relevant model to date for
such in vivo studies. Table 2 summarises the reported changes invarious neurogenesis steps in transgenic mice expressing the FAD
mutated genes for APP or PS.
6. Multi-mutant models
The expression of FAD mutants of APP, PS1 or PS2 can mimic a
feature of AD by increasing the ratio of Aβ1–42/Aβ1–40 peptides, as
well as plaques in the mutant APP transgenic, but the speed of plaque
formation can be slow, and perhaps more importantly the other key
AD pathology of NFT is consistently absent [7,9]. Attempts were
therefore made to increase the severity of the AD pathology through
the co-expression of mutant APP and PS, which further enhance the
production of Aβ and accelerate the formation of plaques [9,91], or to
induce the formation of both plaques and NFT by expressing mutant
APP, PS as well as mutant Tau [92].
In a double knockin line expressing the Swedish APP and the PS1
P264L mutations, both the numbers of NPC and neuroblasts were
decreased at the ages of about 8 and 18 months when Aβ deposits
were present [93]. This study however did not analyse the prolif-
eration and survival rates, or the formation of new neurons, hence
could only provide a limited view on the impact on neurogenesis.
Some of these matters have been addressed in several other studies,
albeit not in knockin models.
Using the double mutations of APPSWE and PS1dE9 expressed
under the regulatory control of the mouse prion promoter, similar
ﬁndings were provided in three reports from two laboratories
[54,94,95]. Firstly measurements of the age-dependent increases in
the Aβ load demonstrates the onset of Aβ deposits at approximately
4–6 months of age, and augmenting thereafter [54,94]. The different
levels of Aβ deposits appeared to have differential effects on
neurogenesis. The proliferation rates in DG of mice at 5–6 months of
Table 2
Effects of FAD mutations in APP or PS on neurogenesis. The speciﬁc steps in
neurogenesis that are increased (↑), decreased (↓) or unchanged (NC) are indicated
under the column “Altered neurogenesis parameters”.
Promoters–
mutations
Changes in
neurogenesis
Altered neurogenesis parameters Reference
APP
PDGF–APPSWE ↓ Proliferation in SGZ and SVZ.
Survival of young neurons.
[52,53]
PrP–APPSWE NC Proliferation in SGZ. [54]
PrP–APPSWE ↓ Survival of new neurons in SGZ. [54]
PDGF–APPSWE ↓ Proliferation in SGZ. [65]
PDGF–APPIND ↓ Proliferation in SGZ at 12 months
independent of plaque load.
[82]
PDGF–APPIND ↓ Survival in SGZ at 12 months
independent of plaque load.
[82]
PDGF–APPIND ↓ Neuroblasts in SGZ at 12 months. [82]
PrP–APPSWE ↓ Neuronal differentiation in SGZ. [54]
Thy1–APPSWE ↑ Proliferation in DG. [78]
Thy1–APPSWE ↑ Neuroblasts in DG. [78]
PDGF–APPSWE/Ind ↑ Proliferation in SGZ and SVZ. [73]
PDGF–APPSWE/Ind ↑ Proliferation in SGZ. [74]
PDGF–APPSWE/Ind ↑ Neuronal differentiation in SGZ. [74]
PrP–APPSWE/Dutch/Lon ↑ Proliferation in SGZ. [79]
PDGF–APPSWE/Ind ↑ NPC number in SVZ at 2 months. [80]
Proliferation DG at 8 months.
PDGF–APPSWE/Ind ↓ NPC number in DG
(8 and 12 months) and
SVZ (12 months).
[80]
Proliferation DG at 12 months.
mThy1–APPSWE,LOND ↓ Proliferation in SGZ. [66]
mThy1–APPSWE,LOND NC Neuronal differentiation in SGZ. [66]
PS
Enolase–PS1P117L ↓ Survival of SGZ progenitors. [87,88]
Knockin–PS1M146V ↓ Proliferation in SGZ neurons. [90]
Knockin–PS1M146V ↓ New SGZ neurons. [90]
Thy1–PS1A246E NC Increased SCZ proliferation
but not mature neurons.
[89]
PrP–PS1dE9 NC Survival of new born cells and
neuronal differentiation in SGZ.
[54]
PrP–PS1dE9 NC Proliferation in SGZ. [54]
Table 3
Effects of combined mutations in APP, PS and tau on neurogenesis. The speciﬁc steps in
neurogenesis that are decreased (↓) or unchanged (NC) are indicated under the column
“Altered neurogenesis parameters”.
Promoters–mutations Changes in
neurogenesis
Altered neurogenesis
parameters
Reference
APP×PS
Knockin–APPSWE×PS1P264L ↓ Reduced DG stem/
progenitors and
neuroblasts.
[93]
PrP–APPSWE×PS1dE9 NC Proliferation in SGZ. [54]
PrP–APPSWE×PS1dE9 ↓ Survival of new born
cells and neuronal
differentiation in SGZ.
[54]
PrP–APPSWE×PS1dE9 ↓ Proliferation and
neuroblasts in GCL
at 9 months but
not 5 months.
[94]
PrP–APPSWE×PS1dE9 ↓ Proliferation SGZ but
not in SVZ at 9 months.
[95]
PrP–APPSWE×PS1dE9 ↓ Survival in SGZ at
9 months.
[95]
Thy1–APPSWE×PS1L166P ↓ Neuroblasts in DG. [78]
Thy1–APPSWE×PS1L166P ↓ NPCs in DG. [78]
APP×PS×Tau
Thy1.2–TauP301L×APPSWE×
knockin PS1M146V
↓ Mitotic marker in SGZ
and SVZ.
[97,98]
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the Aβ deposits becamemuchmore prominent and proliferation and/
or survival of new born cells became reduced, as conﬁrmed by the
quantiﬁcation of cells expressing BrdU and the neuroblast marker
DCX [94,95]. Signiﬁcantly, the suppression of neurogenesis was
further consolidated by the suppression of the long term survival of
new born cells and their differentiation intomature neurons. This ﬁnal
conclusion was based on the reduced percentages of BrdU+ cells co-
labelled for the mature neuron marker NeuN, illustrating that the
reductions in survival and neuronal differentiation are two separate
events. Interestingly, the reduced neural differentiation occurred also
in themutant APPmouse line, at the age of 6 monthswhenAβdeposits
had not been established yet [95]. These neurogenesis suppressive
effects were conﬁrmed in a line with different double transgenes,
namely APPSWE and PS1L166P under the Thy-1 promoter [78].
Although the proliferation rate was not examined, it did show clear
reductions in the quantities of neuroblasts. Additionally, there was a
clear trend for reductions in new born cells and new born neuroblasts,
albeit statistically insigniﬁcant. Nestin+ NPCs were also analysed in
mice derived from the crossing of these APPSWE X PS1L166Pmice with
mice expressing GFP under the promoter for nestin, a marker of NPCs.
Not only was the number of nestin+ NPCs reduced, large proportion
of these cells displayed unusual morphology, with thickened and
hypertrophic neuritic processes that were attracted towards the Aβ
deposits.
Altogether, these studies demonstrate that accelerating and
increasing the severity of Aβ pathology by expressing FAD mutants
of APP and PS result in suppression of multiple steps in the process of
neurogenesis, including the formation of mature neurons.However the absence of NFTs, the other key pathological hallmark
of AD brain, in all the mouse models discussed so far, has left an
important unﬁlled gap. This was fulﬁlled by the triple transgenic
model expressing mutant forms of APP, PS and Tau. Although AD has
not been associated with mutations in the tau gene, mutations in the
tau gene located on chromosome 17 are the underlying causes of
inherited taupathies known as frontotemporal dementia with Parkin-
sonism (FTDP-17), which shares with AD the diagnostic accumulation
of hyperphosphorylated tau as NFTs [96]. Coexpression of the mutant
tau(P301L) with APP(Swe) under the Thy1.2 promoter in the mutant
PS1(M146V) knockin mouse resulted in deﬁcits in synapses and long
term potentiation that manifest in an age-related manner, before the
onset of plaque and tangle pathology [92]. Analysis of proliferation
showed lower number of cells expressing the mitotic marker phos-
phorylated histone H3 (PH3) in both the SGZ and SVZ in an age-
dependent manner, with the more severe deﬁcits occurring in older
mice [97,98]. However, in the absence of more extensive characterisa-
tion of the PH3+ cells and other steps in neurogenesis, the impact of
the triple transgene on neurogenesis remains to be elucidated. Table 3
summarises the reported changes in various neurogenesis steps in
transgenic mice expressing the FAD mutated genes for APP and PS
without or with mutated tau.
7. Concluding remarks
Mounting preclinical evidence from the rodents has increased the
level of belief in a role for hippocampal neurogenesis in learning and
memory although the understanding of neurogenesis biology in
humans remains poor due to the difﬁculties in accessing the human
brain for experimentation. Therefore, suitable animal models are
invaluable research tools. For AD, the FAD mutant mouse models that
were created to study amyloidosis and NFT pathology can address two
related but different aspects of neurogenesis. The recapitulation of AD
neuropathological hallmarks by overexpressing mutant APP, PS and
tau achieves the high amyloid load andNFT that are observed in theAD
human brain, however it is only through the expression of these genes
in their physiological locations and levels by the “knock in” approach
that the regulation of neurogenesis through intracellular pathways
and cell–cell interactions can be addressedwith the greatest biological
relevance. This latter aspect is of particular pertinence due to the well
878 T.T. Chuang / Biochimica et Biophysica Acta 1802 (2010) 872–880established role of PS in regulating multiple cellular pathways beyond
APP processing [2,84], and the emerging role of APP in regulating
neurogenesis via direct bindingwith its ligand Tag-1 [99]. A plethora of
studies using the former approach have been conducted, while only a
handful of studies with this latter model have been reported (Tables 2
and 3). The use of relevant models need to be coupled with thorough
examination across the multiple steps of neurogenesis including the
quantiﬁcation and qualiﬁcation of the neurons generated in the hostile
environment of the FADmousemodel, as in the study of Donovan et al.
[82] (Fig. 2). This report suggests that even in the models where
Aβ stimulated proliferation and/or neuronal differentiation [73,74,
78–80], the resultant neuronal population may be reduced because
these new neurons may be ectopically developed and biologically
abnormal with reduced survival rates due probably to intrinsic defects
and/or failure to innervate correctly. From a therapeutic point of view,
such a scenario would necessitate the development of drugs that can
induce neurogenesis as well as prevent the undesired inﬂuences from
toxic factors related to AD. Therefore, the use of mouse models in AD
has gradually built up an understanding of how neurogenesis could
be impaired in AD, and begins to suggest therapeutic strategies for
the regenerative approach that may supplement other promising
approaches for the patients. To this end, theﬁrst report on the effects of
a potential AD therapeutic agent on neurogenesis demonstrates that
reductions inAβ load in doubly transgenicAPP/PS1mice by passiveAβ
immunotherapy could at least partially rescue impairments in adult
hippocampal neurogenesis, including the survival and morphological
features of new born neurons [100].
Furthermore, the apparent correlation between deﬁcits in neuro-
genesis and AD could also be exploited to provide a novel biomarker.
This is particularly attractive since impaired neurogenesis may precede
the deposition of Aβ plaques, thus providing an early marker of the
disease. It is indeed encouraging that the identiﬁcation of surrogate
markers of hippocampal neurogenesis detectable by non-invasive
technologies are already underway, including the quantiﬁcation of
blood ﬂow in the dentate gyrus by magnetic resonance imaging [101],
as well as the detection of a spectroscopic biomarker by magnetic
resonance spectroscopy [102]. Altogether, these studies demonstrate
the extensive values of the AD mouse models in illuminating our
understanding in the potential involvement of neurogenesis in
AD, which may lead to the development of novel therapeutics and
biomarkers for diagnostic and prognostic purposes.
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